IPHA
Innate Pharma S.A.
NASDAQ · Healthcare · Biotechnology · FR
$2.08
−1.42%Year over year
Reported trailing growth
- Revenue
- -84.8%
- EBITDA
- —
- EBIT
- —
- EPS
- -41.5%
- Free cash flow
- -22.0%
- Operating cash flow
- -24.4%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -63.6%
- EBITDA
- +7.0%
- EBIT
- -3.6%
- Net income
- +0.6%
- EPS
- +13.1%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Dec 1, 2025